Managing Hyperglycemia in Capivasertib Therapy: Key Insights
AstraZeneca's infographic outlines essential strategies for healthcare professionals to manage hyperglycemia in patients undergoing capivasertib treatment.
37% of patients experienced increased fasting glucose levels in the CAPItello-291 trial.
Real-world studies indicate lower hyperglycemia rates with capivasertib compared to other treatments.
Proactive monitoring and specific treatment adjustments are crucial for managing glucose levels.
A recent infographic funded by AstraZeneca provides critical guidelines for healthcare professionals on managing hyperglycemia in patients treated with capivasertib. This resource highlights the importance of proactive measures and monitoring to ensure patient safety and treatment efficacy.
The CAPItello-291 trial revealed that approximately 37% of participants experienced an increase in fasting glucose levels, with the median onset occurring around 15 days after starting treatment. Notably, only 0.6% of patients required dose reductions or permanent discontinuation due to hyperglycemia, indicating that while glucose elevations are a concern, they can be effectively managed.
In a recent observational study conducted in the United States involving patients with metastatic breast cancer, findings suggested that the incidence of hyperglycemia and the need for antihyperglycemic medications were significantly lower in those receiving capivasertib compared to other PI3K/AKT pathway inhibitors. This underscores the potential benefits of capivasertib in managing glucose levels during treatment.
The infographic outlines practical steps for healthcare providers, including proactive preparation before treatment initiation, regular monitoring of fasting glucose levels, and patient counseling. Recommendations include starting or increasing metformin as needed and withholding capivasertib until glucose levels are controlled (≤160 mg/dL). These steps are designed to maintain patient adherence to treatment while managing potential side effects effectively.
Looking ahead, healthcare professionals are encouraged to utilize these guidelines to enhance patient care during capivasertib therapy. Continued monitoring and adjustments based on individual patient responses will be essential in optimizing treatment outcomes and minimizing risks associated with hyperglycemia.
